Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RB1 | P06400 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5463493 | 0.95 | PARP1 (0.55) | PARP1KMT2ACYP2D6LMNASMN1; SMN2 | |
| SCHEMBL5454753 | 0.88 | PARP1 (0.56) | PARP1KMT2AMAPTRB1HTR3A | |
| SCHEMBL5450266 | 0.88 | PARP1 (0.56) | PARP1KMT2AMAPTRB1HTR3A | |
| SCHEMBL5452894 | 0.85 | MAPK1 (0.51) | PARP1KMT2ACYP2C9LMNASMN1; SMN2 | |
| SCHEMBL5459901 | 0.82 | RB1 (0.53) | PARP1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL5459687 | 0.82 | RB1 (0.57) | MAPTRB1ALDH1A1KDM4E | |
| SCHEMBL5468198 | 0.81 | RB1 (0.53) | KMT2ASMN1; SMN2MAPTRB1ALDH1A1 | |
| SCHEMBL5451949 | 0.81 | RB1 (0.56) | KMT2ASMN1; SMN2MAPTRB1KDM4E | |
| SCHEMBL5456566 | 0.81 | RB1 (0.56) | KMT2ASMN1; SMN2MAPTRB1KDM4E | |
| SCHEMBL5449883 | 0.81 | RB1 (0.61) | KMT2ASMN1; SMN2MAPTRB1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | MAVS, SARS1, ZC3HAV1 | PARP1 709/4885KMT2A 4049/4885MAPK14 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.